{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:16:21Z","timestamp":1784211381984,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1093450"],"award-info":[{"award-number":["1093450"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.xphs.2015.10.025","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T06:46:18Z","timestamp":1452581178000},"page":"650-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases"],"prefix":"10.1016","volume":"105","author":[{"given":"Liang","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi (Tony)","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo A.V.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Nicolazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.xphs.2015.10.025_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI16921","article-title":"The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS","volume":"111","author":"Wulff","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00816.x","article-title":"The functional network of ion channels in T lymphocytes","volume":"231","author":"Cahalan","year":"2009","journal-title":"Immunol Rev"},{"issue":"46","key":"10.1016\/j.xphs.2015.10.025_bib3","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"Beeton","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.xphs.2015.10.025_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/187152811797200641","article-title":"Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases","volume":"10","author":"Beeton","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"4","key":"10.1016\/j.xphs.2015.10.025_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.toxicon.2011.07.016","article-title":"Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases","volume":"59","author":"Chi","year":"2012","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.xphs.2015.10.025_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.112.191890","article-title":"Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease","volume":"342","author":"Tarcha","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.xphs.2015.10.025_bib7","series-title":"Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics","first-page":"255","article-title":"Case study 2: transforming a toxin into a therapeutic: the sea anemone potassium channel blocker ShK toxin for treatment of autoimmune diseases","author":"Beeton","year":"2015"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3280321","article-title":"A\u00a0four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom","volume":"328","author":"Lebrun","year":"1997","journal-title":"Biochem J"},{"issue":"12","key":"10.1016\/j.xphs.2015.10.025_bib9","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1110\/ps.8.12.2672","article-title":"Structural and functional consequences of the presence of a fourth disulfide bridge in the scorpion short toxins: solution structure of the potassium channel inhibitor HsTX1","volume":"8","author":"Savarin","year":"1999","journal-title":"Protein Sci"},{"key":"10.1016\/j.xphs.2015.10.025_bib10","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1038\/srep04509","article-title":"A\u00a0potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases","volume":"4","author":"Rashid","year":"2014","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.xphs.2015.10.025_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/bdd.750","article-title":"Diverse approaches for the enhancement of oral drug bioavailability","volume":"32","author":"Fasinu","year":"2011","journal-title":"Biopharm Drug Dispos"},{"issue":"2-3","key":"10.1016\/j.xphs.2015.10.025_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","article-title":"Emerging trends in oral delivery of peptide and protein drugs","volume":"20","author":"Mahato","year":"2003","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-014-1485-1","article-title":"Enhancing the buccal mucosal delivery of peptide and protein therapeutics","volume":"32","author":"Caon","year":"2015","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2015.10.025_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibtech.2009.07.009","article-title":"Therapeutic application of peptides and proteins: parenteral forever?","volume":"27","author":"Antosova","year":"2009","journal-title":"Trends Biotechnol"},{"issue":"6","key":"10.1016\/j.xphs.2015.10.025_bib15","first-page":"495","article-title":"Permeation enhancers in the transmucosal delivery of macromolecules","volume":"61","author":"Sharma","year":"2006","journal-title":"Pharmazie"},{"issue":"4","key":"10.1016\/j.xphs.2015.10.025_bib16","first-page":"367","article-title":"Noninvasive routes of proteins and peptides drug delivery","volume":"73","author":"Jitendra","year":"2011","journal-title":"Indian J Pharm Sci"},{"issue":"1-3","key":"10.1016\/j.xphs.2015.10.025_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0168-3659(93)90179-9","article-title":"Absorption enhancers in nasal drug delivery\u2014efficacy and safety","volume":"24","author":"Merkus","year":"1993","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2015.10.025_bib18","first-page":"361","article-title":"Transdermal donepezil on the treatment of Alzheimer's disease","volume":"8","author":"Sozio","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.xphs.2015.10.025_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2014.12.001","article-title":"Buccal mucosal delivery of a potent peptide leads to therapeutically relevant plasma concentrations for the treatment of autoimmune diseases","volume":"199","author":"Jin","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2015.10.025_bib20","doi-asserted-by":"crossref","DOI":"10.2174\/1872211309666150729122231","article-title":"Recent patents in pulmonary delivery of macromolecules","author":"Ray","year":"2015","journal-title":"Recent Pat Drug Deliv Formul"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"9-10","key":"10.1016\/j.xphs.2015.10.025_bib22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.addr.2006.07.012","article-title":"In\u00a0vivo, in\u00a0vitro and ex\u00a0vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery","volume":"58","author":"Sakagami","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.xphs.2015.10.025_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1023\/A:1015851521551","article-title":"The pharmacokinetics of pulmonary-delivered insulin\u2014a comparison of intratracheal and aerosol administration to the rabbit","volume":"9","author":"Colthorpe","year":"1992","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1023\/A:1016081301369","article-title":"Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats","volume":"13","author":"Kobayashi","year":"1996","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(92)90024-V","article-title":"A\u00a0new approach for insulin delivery via the pulmonary route\u2014design and pharmacokinetics in nondiabetic rabbits","volume":"86","author":"Sakr","year":"1992","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2015.10.025_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/00365519609088614","article-title":"An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs","volume":"56","author":"Jendle","year":"1996","journal-title":"Scand J Clin Lab Invest"},{"issue":"7","key":"10.1016\/j.xphs.2015.10.025_bib28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1023\/A:1018999707476","article-title":"Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog","volume":"11","author":"Bennett","year":"1994","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2015.10.025_bib29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/jps.2600830621","article-title":"Intratracheal delivery of peptide and protein agents\u2014absorption from solution and dry powder by rat lung","volume":"83","author":"Komada","year":"1994","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2015.10.025_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1023\/A:1018951824315","article-title":"Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep","volume":"11","author":"Schreier","year":"1994","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2015.10.025_bib31","first-page":"917","article-title":"Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats","volume":"25","author":"Taljanski","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"1-3","key":"10.1016\/j.xphs.2015.10.025_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0378-5173(92)90304-K","article-title":"Intratracheal delivery of insulin absorption from solution and aerosol by rat lung","volume":"88","author":"Okumura","year":"1992","journal-title":"Int J Pharm"},{"issue":"1-3","key":"10.1016\/j.xphs.2015.10.025_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0168-3659(94)90155-4","article-title":"Bioavailability of pulmonary delivered peptides and proteins\u2014alpha-interferon, calcitonins and parathyroid hormones","volume":"28","author":"Patton","year":"1994","journal-title":"J\u00a0Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2015.10.025_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4331\/wjbc.v3.i4.73","article-title":"Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges","volume":"3","author":"Vugmeyster","year":"2012","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.xphs.2015.10.025_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2466-13-72","article-title":"Qualitative assessment of attributes and ease of use of the ELLIPTATM dry powder inhaler for delivery of maintenance therapy for asthma and COPD","volume":"13","author":"Svedsater","year":"2013","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.xphs.2015.10.025_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.03.006","article-title":"Emerging inhalation aerosol devices and strategies: where are we headed?","volume":"75","author":"Zhou","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2015.10.025_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1293\/tox.19.107","article-title":"A\u00a0reliable method for intratracheal instillation of materials to the entire lung in rats","volume":"19","author":"Oka","year":"2006","journal-title":"J\u00a0Toxicol Pathol"},{"issue":"3","key":"10.1016\/j.xphs.2015.10.025_bib38","first-page":"256","article-title":"Transoral tracheal intubation of rodents using a fiberoptic laryngoscope","volume":"36","author":"Costa","year":"1986","journal-title":"Lab Anim Sci"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0013-9351(76)90107-9","article-title":"Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation","volume":"11","author":"Brain","year":"1976","journal-title":"Environ Res"},{"issue":"3","key":"10.1016\/j.xphs.2015.10.025_bib40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/mp500745v","article-title":"Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus","volume":"12","author":"Liang","year":"2015","journal-title":"Mol Pharm"},{"issue":"15","key":"10.1016\/j.xphs.2015.10.025_bib41","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1523\/JNEUROSCI.5591-09.2010","article-title":"Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy","volume":"30","author":"Glasscock","year":"2010","journal-title":"J\u00a0Neurosci"},{"issue":"24","key":"10.1016\/j.xphs.2015.10.025_bib42","doi-asserted-by":"crossref","first-page":"13942","DOI":"10.1073\/pnas.241497298","article-title":"Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis","volume":"98","author":"Beeton","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xphs.2015.10.025_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2014.11.008","article-title":"Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat","volume":"68","author":"Amancha","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2015.10.025_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijpharm.2003.09.033","article-title":"Transport of proteins and peptides across human cultured alveolar A549 cell monolayer","volume":"269","author":"Wang","year":"2004","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2015.10.025_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-9120(01)00196-5","article-title":"Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones","volume":"34","author":"Evans","year":"2001","journal-title":"Clin Biochem"},{"issue":"12","key":"10.1016\/j.xphs.2015.10.025_bib46","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1248\/cpb.48.1921","article-title":"Pharmacokinetic disposition of polyethylene glycol-modified salmon calcitonins in rats","volume":"48","author":"Yoo","year":"2000","journal-title":"Chem Pharm Bull"},{"issue":"3","key":"10.1016\/j.xphs.2015.10.025_bib47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1023\/A:1016292232513","article-title":"The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth-hormone in rabbits","volume":"12","author":"Colthorpe","year":"1995","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2015.10.025_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2004.01.027","article-title":"Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats","volume":"96","author":"Bosquillon","year":"2004","journal-title":"J\u00a0Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2015.10.025_bib49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.xphs.2015.10.025_bib50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/ppa.13.47","article-title":"Inhaled antibiotics to treat lung infection","volume":"2","author":"Cipolla","year":"2013","journal-title":"Pharm Pat Anal"},{"issue":"11","key":"10.1016\/j.xphs.2015.10.025_bib51","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/dia.2009.0062","article-title":"Safety and efficacy of inhaled human insulin (Exubera\u00ae) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial","volume":"11","author":"Rosenstock","year":"2009","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.xphs.2015.10.025_bib52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A\u00a0two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"J\u00a0Pediatr"},{"issue":"1-2","key":"10.1016\/j.xphs.2015.10.025_bib53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.brainres.2004.04.034","article-title":"Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin","volume":"1014","author":"Brown","year":"2004","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.xphs.2015.10.025_bib54","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.bbamem.2015.06.011","article-title":"Characterization of the direct interaction between KcsA-Kv1.3 and its inhibitors","volume":"1848","author":"Xu","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2003.10.001","article-title":"Absorption enhancers in pulmonary protein delivery","volume":"94","author":"Hussain","year":"2004","journal-title":"J\u00a0Control Release"},{"issue":"2","key":"10.1016\/j.xphs.2015.10.025_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0005-2736(96)00024-7","article-title":"Molecular cloning and tissue distribution of rat peptide transporter PEPT2","volume":"1280","author":"Saito","year":"1996","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.xphs.2015.10.025_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/thorax.57.1.55","article-title":"Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung","volume":"57","author":"Groneberg","year":"2002","journal-title":"Thorax"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491500026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491500026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T07:21:24Z","timestamp":1537082484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491500026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S002235491500026X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2015.10.025","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2015.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}